MINT-ALENDRONATE TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

ALENDRONIC ACID (ALENDRONATE SODIUM)

متاح من:

MINT PHARMACEUTICALS INC

ATC رمز:

M05BA04

INN (الاسم الدولي):

ALENDRONIC ACID

جرعة:

10.0MG

الشكل الصيدلاني:

TABLET

تركيب:

ALENDRONIC ACID (ALENDRONATE SODIUM) 10.0MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

28

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

BONE RESORPTION INHIBITORS

ملخص المنتج:

Active ingredient group (AIG) number: 0150323003; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2018-08-01

خصائص المنتج

_Product Monograph – _
MINT-ALENDRONATE
_ _
_ Page 1 of 47 _
PR O D U CT MON OGR A PH
MINT-ALENDRONATE
ALENDRONATE SODIUM TABLETS
5 MG, 10 MG AND 70 MG
Bone Metabolism Regulator
Mint Pharmaceuticals Inc.
1093 Meyerside Drive, Unit 1
Mississauga, Ontario
L5T 1J6
Date of Revision:
April 19, 2018
SUBMISSION CONTROL NO.: 214834
_Product Monograph – _
MINT-ALENDRONATE
_ _
_ Page 2 of 47 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION .............................
3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................
13
DOSAGE AND ADMINISTRATION
......................................................................................
14
OVERDOSAGE
.......................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 16
STORAGE AND STABILITY
.................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 21
PART II: SCIENTIFIC INFORMATION
............................................... 22
PHARMACEUTICAL INFORMATION
.................................................................................
22
CLINICAL TRIALS
.........................................................